Vaxzevria (previously COVID-19 Vaccine AstraZeneca)


COVID-19 Vaccine (ChAdOx1-S [recombinant])

This medicine is authorised for use in the European Union.


Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus.

Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2.

Vaxzevria does not contain the virus itself and cannot cause COVID-19.

Detailed information about this vaccine is available in the product information, which includes the package leaflet.

This EPAR was last updated on 18/01/2022

Authorisation details

Product details
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
Agency product number
Active substance
International non-proprietary name (INN) or common name
COVID-19 Vaccine (ChAdOx1-S [recombinant])
Therapeutic area (MeSH)
COVID-19 virus infection
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Conditional approvalConditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.

Publication details
Marketing-authorisation holder
AstraZeneca AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

151 85 Sodertalje

Product information

14/01/2022 Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - EMEA/H/C/005675 - II/0055


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

Assessment history

Safety updates


Related content

How useful was this page?

Add your rating
105 ratings
59 ratings
30 ratings
29 ratings
101 ratings